Supplementary Figure S2. from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target

Takuma Yoshimura; Takashi Kamatani; Aki Ookubo; Mio Takahashi; Manabu Itoh; Toshiki Ebisudani; Yohei Masugi; Tomomi Toyonaga; Junko Hamamoto; Keiko Saotome; Kensuke Sakai; Tomoko Yoshihama; Nobuko Moritoki; Shinsuke Shibata; Hiroyuki Yasuda; Toshiro Sato; Taka-Aki Sato; Daisuke Aoki; Wataru Yamagami; Tatsuhiko Tsunoda; Tatsuyuki Chiyoda

doi:10.1158/2767-9764.29645826

Key Points

High-throughput screening showed that clear cell ovarian cancer organoids are vulnerable to proteasome inhibitors and dinaciclib.
Immunoblot analysis confirmed the successful knockout of AGR2 in low AGR2 expressing clear cell ovarian cancer organoids.
Despite AGR2 knockout, there was no significant suppression of cell growth in AGR2-low clear cell ovarian cancer organoids.
Identifying AGR2 as a therapeutic target could enhance treatment strategies for clear cell ovarian cancer.

Implication

High-throughput screening reveals clear cell ovarian cancer vulnerabilities to proteasome inhibitors and dinaciclib, indicating AGR2 as a potential therapeutic target.

Abstract

AGR2-knockout (KO) in AGR2-low clear cell ovarian cancer (CCC) did not suppress cell growth A, Immunoblot analysis confirmed AGR2 KO. B, AGR2 KO did not suppress cell growth in AGR2-low CCC organoid (18-015).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yoshimura et al. (2025) studied this question.

synapsesocial.com/papers/689a0f8de6551bb0af8d0d4c https://doi.org/10.1158/2767-9764.29645826

View at Publisher

Ask AI

Bookmark

Share

Supplementary Figure S2. from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S2. from High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers